Advanced Unresectable Solid Tumors, BRAF-mutated Tumors
Conditions
Brief summary
The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of FORE8394.
Detailed description
Dose Escalation (Part 1): To evaluate safety, pharmacokinetics, pharmacodynamics of FORE8394 in adult and pediatric patients with advanced BRAF- mutated tumors, and to identify the recommended Phase 2 Dose. Dose Extension (Part 2): To access objective tumor response to FORE8394 treatment in adult and in adolescent patients with advanced BRAF- mutated tumors, to access RECIST, and to access pharmacokinetics, pharmacodynamics, and safety.
Interventions
DRUGFORE8394
Sponsors
Fore Biotherapeutics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
10 Years to No maximum
Healthy volunteers
No
Inclusion criteria
- Group A: * Age ≥ 10 years and at least 30 kg. * Phase 1-Dose Escalation (no longer enrolling as of Protocol Amendment 10): Patients with histologically confirmed advanced solid tumors who are refractory to, relapsed after, or intolerant to standard therapy or for whom no standard therapy exists. * Phase 2a-Dose Extension: Criteria for Dose Extension \[HME\] Cohort 1 or Cohort 2, are specified below: * Phase 2a-Dose Extension-Cohort 1 1. Patients with solid tumors (as of Amendment 10, only subjects with glioma tumors) driven by an activating BRAF-V600 mutation 2. Patients with no prior exposure to BRAF-directed therapy and for whom no standard therapy exists. * Phase 2a-Dose Extension-Cohort 2 1. Patients with solid tumors driven by an activating BRAF non-V600 mutation, which can include a point mutation, gene amplification, fusion, insertion, or deletion 2. Participants with no prior exposure to BRAF-directed therapy and for whom no standard therapy exists. * Phase 2a - RP2D Redefinition Extension: Following RP2D redefinition, extension participants must meet criteria for Cohort 3 or Cohort 4 as specified below: 1. Cohort 3: Participants with advanced unresectable gliomas driven by an activating BRAF V600 or activating non-V600 mutation who have no prior exposure to a BRAF, MEK, or ERK inhibitor and for whom no standard therapy exists. 2. Cohorts 4-8: Participants with advanced solid tumors driven by activating BRAF non V600 mutations, which can include a point mutation, gene amplification, fusion, insertion, deletion, or alternative splicing, who have no prior exposure to a BRAF, MEK, or ERK inhibitor. * Measurable disease by RECIST 1.1. * RANOS (CNS tumors) - High Grade Glioma for high grade glioma (Grades 3 and 4) and RANO-Low Grade Glioma for low grade glioma. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Adequate hematologic, hepatic, and renal function. * Women of child-bearing potential must have a negative pregnancy test and must agree to use an effective form of contraception from the time of the negative pregnancy test up to 3 months after the last dose of study drug. Women of non-child-bearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥ 1 year. * Fertile men must agree to use an effective method of birth control during the study and for up to 3 months after the last dose of study drug. * Completion of previous anti-cancer therapy at least 2 weeks before study drug initiation.
Exclusion criteria
- Group A: * Participants with known co-occurring RAS-related mutations or RTK activation are not allowed. * Major surgical procedure, open biopsy (excluding skin cancer resection), or significant traumatic injury within 14 days of initiating study drug or anticipation of the need for major surgery during the study. * Uncontrolled intercurrent illness. * Patients with colorectal cancer or pancreatic cancer * Active secondary malignancy unless the malignancy is not expected to interfere with the evaluation of safety and is approved by the Medical Monitor. Patients with a completely treated prior malignancy and no evidence of disease for ≥ 2 years are eligible. * Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption. * Clinically significant cardiac disease. * Known infection with HIV, HBV, or HCV or a known carrier of HBV or HCV.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the overall response rate of FORE8394 treatment at the applicable RP2D in a) Group A, Cohort 1, and b) Group A, Cohort 2. | 5 years |
| Compare Cmax of FORE8394 with FORE8394 | First dose of FORE8394 up to 30 days after end of treatment |
| Compare Tmax of FORE8394 with FORE8394 | First dose of FORE8394 up to 30 days after end of treatment |
| Compare T1/2 of FORE8394 with FORE8394 | First dose of FORE8394 up to 30 days after end of treatment |
| Area under the curve (AUC) of FORE8394 | First dose of FORE8394 up to 30 days after end of treatment |
| Maximum concentration (Cmax) of FORE8394 | First dose of FORE8394 up to 30 days after end of treatment |
| Time to peak concentration (Tmax) of FORE8394 | First dose of FORE8394 up to 30 days after end of treatment |
| Half life (T1/2) of FORE8394 | First dose of FORE8394 up to 30 days after end of treatment |
| Number of participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v4.0. | First dose of FORE8394 up to 30 days after end of treatment |
| To identify the recommended Phase 2 dose (RP2D) of FORE8394 in Group A (adult patients) for further evaluation in Dose Extension. | 2 years |
| Compare AUC of FORE8394 with FORE8394 | First dose of FORE8394 up to 30 days after end of treatment |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the progression free survival (defined as time of first dose to progressive disease or death) at the applicable RP2D in Dose Extension. | 5 years |
| Clinical benefit rate (defined as stable disease, partial response and complete response) after 24 weeks on study | 5 years |
| To evaluate the duration of response (defined as time of initial response to progressive disease or death) at the applicable RP2D in Dose Extension. | 5 years |
Countries
United States
Outcome results
None listed